Full Press Release Details
CureVac Announces Voting
Results of General Meeting
T BINGEN, Germany / BOSTON, USA -
June 19, 2023 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class
of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's
annual general meeting.
The shareholders of the Company voted in
favor of all proposals. The proposals voted in favor for included the appointment of Michael Brosnan as member of the Supervisory
Board effective June 19th, 2023, and the
appointment of KPMG Accountants N.V. as the external auditors for the financial year 2024.
A table containing tabulations of the votes casted is expected to
be released in the coming days.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020,
CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on
CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T bingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
Forward-Looking Statements CureVac
This press release contains statements that constitute
"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.
and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services
GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include statements regarding the completion, size
and terms of the proposed public offering. In some cases, you can identify such forward-looking statements by terminology such as "anticipate,"
"intend," "believe," "estimate," "plan," "seek," "project," or
"expect," "may," "will," "would," "could," "potential," "intend,"
or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's
current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are
not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements
are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing
instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical
studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration
partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation,
regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects
of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the
effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned
not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual
results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made
only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or
to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required
For further information, please reference the
company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at www.sec.gov.